Elizabeth M Brunt

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8072815/elizabeth-m-brunt-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61 13,328 29 59 h-index g-index citations papers 61 16,590 8.3 6.42 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
59	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD <i>Journal of Hepatology</i> , 2022 ,	13.4	5
58	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022 , 5, 61-90	0.3	О
57	Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers <i>Cancer Genetics</i> , 2022 , 264-265, 90-99	2.3	1
56	Banff consensus recommendations for steatosis assessment in donor livers. Hepatology, 2021,	11.2	2
55	Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. <i>Hepatology</i> , 2021 , 74, 1203-1219	11.2	14
54	Fifty years of impact on liver pathology: a history of the Gnomes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 478, 191-200	5.1	
53	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021 , 73, 2028-2038	11.2	31
52	Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
51	Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis. <i>Journal of Lipid Research</i> , 2021 , 100123	6.3	O
50	Deep learning quantification of percent steatosis in donor liver biopsy frozen sections. <i>EBioMedicine</i> , 2020 , 60, 103029	8.8	12
49	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. <i>PLoS ONE</i> , 2019 , 14, e0221683	3.7	29
48	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019 , 2, e1912565	10.4	108
47	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. <i>Hepatology</i> , 2019 , 70, 522-531	11.2	58
46	cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. <i>Hepatology</i> , 2018 , 68, 113-126	11.2	164
45	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 67, 328-357	11.2	2641
44	Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018 , 67, 858-872	11.2	78
43	Hepatocellular carcinoma: Where are we in 2018?. Current Problems in Surgery, 2018, 55, 450-503	2.8	1

42	Challenges in the hepatic histopathology in non-alcoholic fatty liver disease. <i>Gut</i> , 2017 , 66, 1539-1540	19.2	10
41	Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of the American College of Surgeons</i> , 2017 , 225, 28-40	4.4	19
40	Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2017 , 65, 1543-1556	11.2	82
39	When is it NAFLD and when is it ALD? 2016 , 72-81		1
38	Terminal hepatic venule injury in liver biopsies of allogeneic haematopoietic stem cell recipients-a study of 63 cases. <i>Histopathology</i> , 2016 , 68, 996-1003	7-3	3
37	Acidophil bodies in nonalcoholic steatohepatitis. <i>Human Pathology</i> , 2016 , 52, 28-37	3.7	8
36	Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	53
35	Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. <i>Brain</i> , 2016 , 139, 2909-2922	11.2	70
34	Anatomic pathology of hepatocellular carcinoma: histopathology using classic and new diagnostic tools. <i>Clinics in Liver Disease</i> , 2015 , 19, 239-59	4.6	16
33	Well-differentiated hepatocellular neoplasm of uncertain malignant potentialreply. <i>Human Pathology</i> , 2015 , 46, 635-6	3.7	4
32	Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. <i>Hepatic Oncology</i> , 2015 , 2, 255-273		35
		4	
31	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15080	51.1	
30	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15080 Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1468	51.1	
	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary)	51.1	366
30	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1468 Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature. <i>Diagnostic</i>	51.1 3- 7 3	366 8
30	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1468 Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature. <i>Diagnostic Pathology</i> , 2015 , 10, 81	51.1 3-73	366 8 20
30 29 28	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1468 Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature. <i>Diagnostic Pathology</i> , 2015 , 10, 81 Pathological features of fatty liver disease. <i>Gastroenterology</i> , 2014 , 147, 754-64 Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly	51.1 3-73 3	366 8 20 226

24	Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. <i>Journal of Biological Chemistry</i> , 2014 , 289, 30177-88	5.4	31
23	Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. <i>Modern Pathology</i> , 2014 , 27, 420-32	9.8	28
22	Role of liver biopsy in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 9020	6-3 <i>t</i>	104
21	Pathology of NAFLD 2013 , 27-36		2
20	A novel genetic marker of liver disease aetiology in hepatocellular carcinoma: culling the metabolic syndrome. <i>Gut</i> , 2013 , 62, 808-9	19.2	3
19	Histopathologic features of hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012 , 1, 194-199	2.2	11
18	Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. <i>Digestive Diseases</i> , 2012 , 30 Suppl 1, 61-8	3.2	29
17	Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2011 , 55, 654-659	13.4	181
16	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. <i>Hepatology</i> , 2011 , 53, 810-20	11.2	712
15	Non-alcoholic fatty liver disease: what's new under the microscope?. <i>Gut</i> , 2011 , 60, 1152-8	19.2	23
14	Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2010, 16, 5286-96	5 5.6	262
13	Pathology of nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 195-203	24.2	350
12	Hepatic progenitor cell proliferation and liver injury in 🗈 -antitrypsin deficiency. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010 , 51, 626-30	2.8	20
11	Gender dimorphic formation of Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. <i>FASEB Journal</i> , 2010 , 24, 757.7	0.9	
10	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. <i>Hepatology</i> , 2009 , 49, 809-20	11.2	265
9	Reply:. <i>Hepatology</i> , 2009 , 49, 2127-2128	11.2	
8	Reply:. <i>Hepatology</i> , 2009 , 50, 321-322	11.2	
7	Histopathology of non-alcoholic fatty liver disease. <i>Clinics in Liver Disease</i> , 2009 , 13, 533-44	4.6	90

LIST OF PUBLICATIONS

6	Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. <i>Journal of Hepatology</i> , 2008 , 48, 821-8	13.4	182
5	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005 , 41, 1313-21	11.2	6503
4	Infarction in focal nodular hyperplasia of the liver. A case report. <i>American Journal of Clinical Pathology</i> , 1991 , 95, 503-6	1.9	15
3	Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report. <i>Hepatology</i> , 1991 , 13, 1017-1021	11.2	57
2	Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. <i>Hepatology</i> , 1990 , 11, 59-64	11.2	93
1	Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. <i>Journal of Infectious Diseases</i> , 1990 , 161, 454-61	7	68